Regeneron Pharmaceuticals, Inc. $(REGN)$ and Sanofi recently announced results from the DISCOVER Phase 4, single-arm, open-label trial of Dupixent® (dupilumab) in adults and adolescents with moderate-to-severe atopic dermatitis with skin of color. The results were presented at the 2025 Revolutionizing Atopic Dermatitis $(RAD)$ Conference. This trial marks the first clinical investigation of Dupixent in a large population with darker skin tones. Findings demonstrated significant improvements in disease severity, with 76% of participants achieving a 75% or greater improvement. Notable reductions in hyperpigmentation, dry skin, and itch were also observed. The safety profile was consistent with existing data, and the trial supports a commitment to advancing the understanding of chronic diseases in communities of color.